Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults
Shots:
- NeoCart is a P-III cell therapy platform technology, a 3D tissue-engineered disc of new cartilage that is manufactured from growing chondrocytes to repair full-thickness lesions of the knee cartilage in adults
- It accelerates healing, reduces pain by rebuilding the damaged knee cartilage, creates a functional joint surface similar to that prior injury & prevents progression of osteoarthritis
- Ocugen and US FDA are working towards finalizing the necessary market authorization of NeoCart. Additionally, in 2019 NeoCart was acquired by Ocugen from its original developer, Histogenics
Ref: Ocugen | Image: Ocugen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
